Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 137

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 137
---
a and in 2022 was £0.21 million in respect of impairment of a loan to Bioasis.

Cash Used in Operations.
Working capital increased in cash flow terms by £0.87 million for the first six months of 2024, compared to a decrease of £0.21
million for the same period in 2023. The increase in the six months ended June 30, 2024 primarily comprised an increase in trade
and other receivables of £1.30 million offset by a decrease in trade and other payables provisions of £0.43 million.

Working capital increased in cash flow terms by £0.05 million for the year ended December 31, 2023, compared to a decrease of £0.52 million for 2022. The increase in 2023 primarily comprised of an increase in trade and other payables of £0.21 million offset by the utilization of £0.21 million provision in respect of expected losses on a loan provided to Bioasis and a reduction in debtors of £0.37 million.

Taxes Paid. Taxes paid
in the six months ended June 30, 2023 and 2022 were £nil. Taxes paid in the years ended December 31, 2023 and 2022 were £nil.

Research and development tax credits of £0.84 million were received in 2023, as opposed to £0.68 million in 2022. This related to claims submitted in the prior financial year.

Investing Activities

There was no purchase of property,
plant and equipment in the first six months of 2024, compared to £4,000 in the first six months of 2023. Capital expenditures in
2023 related to laboratory equipment. In addition, we acquired the eRapa license for total consideration of £3.07 million including
cash consideration of £0.85 million. These cash outflows are offset by interest income from bank deposits of £0.10 million.

Purchase of property, plant and equipment of £0.03 million occurred in the year ended December 31, 2023, compared to £0.06 million in 2022. In addition, we acquired the tolimidone license for total consideration of £2.94 million, including cash of £0.24 million. These cash outflows are offset interest income from bank deposits of £0.07 million.

Financing Activities

Amounts paid on lease liabilities.In the six months ended June